Anastasia L. Armbruster

Vasopressors, Vasodilators, and Antithrombotics in the Catheterization Laboratory

Joseph S. Van Tuyl, Anastasia L. Armbruster

Pharmacologic management plays a vital role in cardiovascular interventions within the catheterization laboratory, particularly in the administration of vasopressors, vasodilators, and antithrombotic agents. This chapter provides an in-depth review of these therapeutic classes, examining their mechanisms of action, indications, and clinical applications. …

Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement

Dharam J. Kumbhani, Anastasia L. Armbruster, Richard K. Cheng, Jonathan Chrispin et autres

Evaluation of Apixaban Use in Patients With Advanced Kidney Disease

Conner McClain, Amanda R. Buckallew, Anastasia L. Armbruster

Background: Current guidelines and literature suggest apixaban may be used in patients with severe kidney disease and atrial fibrillation (AF) for stroke and systemic embolism risk reduction (SSE) or patients with acute venous thromboembolism (VTE). Limited data is available for long-term safety …

us (code pays fourni par la source)

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation

José A. Joglar, Mina K. Chung, Anastasia L. Armbruster, Emelia J. Benjamin et autres

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

José A. Joglar, Mina K. Chung, Anastasia L. Armbruster, Emelia J. Benjamin et autres

AIM: The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing …

us, nl (code pays fourni par la source)

Assessing the utility of pre-course assessment and voluntary pre-work in two required integrated pharmacotherapy courses

Laura Challen, Joseph S. Van Tuyl, Suzanne G. Bollmeier, Jasna Marjanovic et autres

us (code pays fourni par la source)

2022 ACC/AHA guideline for the diagnosis and management of aortic disease

Eric M. Isselbacher, Ourania Preventza, James H. Black, John Augoustides et autres

2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure

Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, Larry A. Allen et autres

Four-Drug Therapy for Heart Failure With Reduced LV Ejection Fraction: Here and Now

Anastasia L. Armbruster, Douglas L. Mann, Justin Vader

us (code pays fourni par la source)

The role of inflammation in the pathogenesis and treatment of arrhythmias

Anastasia L. Armbruster, Kristen Bova Campbell, Milan Kahanda, Phillip S. Cuculich

Abstract The pathogenesis of arrhythmias is complex and multifactorial. The role of inflammation in the pathogenesis of both atrial and ventricular arrhythmias (VA) has been explored. However, developing successful pharmacotherapy regimens based on those pathways has proven more of a challenge. This …

us (code pays fourni par la source)

Key Points for Pharmacists From the ACC Expert Consensus Decision Pathway for Patients Hospitalized With Heart Failure

Katie B. Tellor, Anastasia L. Armbruster

Heart failure (HF) is a complex condition, and its clinical course often includes periods of decompensation that represent a deterioration in clinical status. During these periods, patients may experience worsening HF symptoms requiring hospitalization. Heart failure that necessitates hospitalization increases the risk …

us (code pays fourni par la source)

Utilization of EKOS in Patients With Pulmonary Embolism

Kirsten E. Robles, Anastasia L. Armbruster, Shane E. Austin, Joshua N. Baker

Objective: Current guidelines recommend utilization of catheter-directed thrombolysis systems for management of patients with submassive pulmonary embolism (PE) who have relative contraindications to systemic thrombolysis. Evidence from previous trials have demonstrated the short-term efficacy and safety of one of these systems, the …

us (code pays fourni par la source)